These biomarkers gave insight into complexity and heterogeneity of vascular changes in gliomas to differentiate HGGs versus LGGs.50 Furthermore, combining multiparametric quantitative blood oxygenation level-dependent approach (qBOLD) with VAM parameters helped distinguish LGGs versus HGGs and identify isocitrate dehydrogenase (IDH) mutation status with higher sensitivity.50 Stadlbauer et al.51 also performed analysis of vascular hysteresis loop (VHLs) in combination with the VAM biomarkers to assess response of glioblastoma to anti-angiogenic therapy. This evidence concerns the gene IDH1 and central nervous system cancer.